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DOI 10.1016/j.chembiol.2011.03.003Every unmet medical need has its own
version of the ‘‘holy grail.’’ For cartilage
biologists, that search leads to cartilage
repair. By the time people see orthopedic
surgeons for tender knees, achy backs, or
painful hands, joint damage is well un-
derway. Once damage to cartilage and
bone shows up on an X-ray, joints have
already suffered irreversible harm.
On the good side, cartilage allows joints
to glide and bounce. On the worrisome
side, cartilage has a limited blood supply
and thus a limited ability to heal. Like un-
repaired chips along the surface of an
ice rink, the tiny defects in cartilage from
injury or wear and tear worsen over time.
Chips turn into chunks, joint motion
changes, and damage progresses to
osteoarthritis, cartilage damage that
extends to bone. Orthopedic surgeons
consider this end-stage joint disease,
leaving few options other than joint
replacement.
According to an article in START-UP,
a magazine covering the business of
healthcare, as of 2009 there were 40 com-
mercial efforts aimed at cartilage repair
(Stuart, 2009). St. Louis-based ISTO
Technologies is part of those efforts.
ISTO licensed the technology from BJC
Health Care in St. Louis to form the com-
pany. Mid-America Transplant Services in
St. Louis was the major investor for the
initial million dollars of capitalization and
also provided space at their facility to
initiate the research and to help the
company get started in 1997.
Today ISTO Technologies has four
programs: two are biologics, Denovo
ET engineered cartilage tissue for knees
andDenovoNT, natural tissue for cartilage
repair in any joint. Both are distributed by
Zimmer, the company’smarketing partner
for these biologics since 2002. The other
two are NuQu (also a biological platform),
an injectible percutaneous delivery of
chondrocytes to damaged spinal discs,
and InQu, a bone graft substitute.
Annually, there are approximately
500,000 cartilage repair surgeries in the
US on knees alone. People with damagedknees have few options. Surgeons can
shave damaged cartilage or drill holes
down to the bone or make microfractures
to stimulate healing, but cartilage formed
from those procedures is fibrocartilage
and not the sturdy hyaline cartilage found
in joints. Thus far, the only FDA-approved
articular cartilage repair product is Gen-
zyme’s Carticel or ACI (autologous carti-
lage implantation). In this procedure, the
patient’s own chondrocytes are har-
vested, sent to a lab for expansion, and
then reintroduced into the damaged joint
approximately four weeks later, after
enough cells have grown. ACI is not ideal,
say industry experts, because the tech-
nique requires two surgeries and can
cost up to $26,000.
Mitchell Seyedin, Ph.D., president and
CEO of ISTO Technologies, says the
company has come up with a way to
replace damaged cartilage in one proce-
dure with laboratory-grown cartilage.
ISTO uses juvenile human chondrocytes
from donors procured throughMid-Amer-
ican Transplant services and other organ
procurement organizations. To make the
laboratory cartilage, company scientists
tease out cartilage cells from the dense
extracellular matrix, expand them, and
then put them in special cultures without
the need for a scaffold. After a month or
so, the chondrocytes form cartilage discs
about the size of a quarter and nearly
identical in toughness and composition
to hyaline cartilage. Because chondro-
cytes can be expanded in one of ISTO’s
many patented techniques, chondrocytes
from a single donor can be expanded and
frozen for future use and also cultured into
Denovo ET, meaning that a single donor
can treat thousands of patients.
Zimmer has dubbed this cell-based
therapy Denovo ET (for engineered
tissue). These cartilage discs can be
delivered to surgeons who cut them to
the size of the defect, dab on some fibrin
glue, and then patch the hole in the carti-
lage. Eventually, the engineered cartilage
blends in with the surrounding cartilage.
Phase I and II clinical trials have alreadyChemistry & Biology 18, March 25, 2011been completed. The primary outcome
measure was KOOS (knee injury and
outcome score), in which patients assess
their pain levels. Those data have not
been published.
For Denovo NT (natural tissue), the
donated cartilage is minced and sent to
orthopedic surgeons, who then implant
the tissue directly into chondral defects.
Fibrin made from the patient’s blood
holds the tissue in place. So far about
2000 patients have been treated over
the past 2 years, mostly in knee and ankle
joints, says Cheryl Blanchard, Ph.D.,
senior vice president and CSO at Zimmer
and a member of ISTO’s board of direc-
tors. Because Denovo NT is a tissue
transplant, no premarket clinical trials
were needed. Zimmer is, however, con-
ducting postmarket studies and preparing
them for publication.
Actually, Blanchard says Zimmer is
getting barraged with anecdotal results,
including those from professional athletes
and extremely active people like downhill
skiers who have returned to their sports
pain free. ‘‘That’s a big deal because
you don’t hear those stories very often,’’
says Blanchard. ‘‘It’s really a significant
innovation in the development of mean-
ingful cartilage repair technology.’’ Blan-
chard says she chooses to say ‘‘meaning-
ful’’ because Denovo NT requires one
treatment, unlike ACI. While Zimmer
doesn’t publish the cost, Blanchard says
Denovo NT is ‘‘significantly less than
ACI.’’
Blanchard mentioned a few caveats,
though. She says that Denovo NT is
‘‘very promising’’ but is still new and
needs a few more years of treatment to
measure the outcomes of the therapy.
The larger issue with Denovo NT is that
of the donated nature of the tissue.
Although one donor can treat more than
one person, there will always be some
degree of supply constraint. ‘‘This tissue
is a gift that families give when a child
has passed away and that’s a very difficult
decision to make. A whole bunch of
people can get their lives back becauseª2011 Elsevier Ltd All rights reserved 275
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While it is a gift, it is a difficult thing to
manage the supply and demand logistic
just like with any transplant,’’ says
Blanchard.
Unlocking Cartilage Biology
The laboratory techniques that turned
ISTO’s cell-based therapies into a com-
mercial platform were years in the
making. Chief scientist H. Davis Adkisson,
Ph.D., began studying cartilage biology
as a graduate student in the early 1990s,
work that continues today. Adkisson
began by looking for characteristics that
made cartilage different from tissues that
have a blood supply. Adkisson reasoned
that because cartilage doesn’t have
a blood supply, chondrocytes found
a way to flourish in the dense extracellular
matrix without certain nutrients, such as
dietary essential fatty acids. Indeed,
when Adkisson enriched chondrocytes
cultures in fatty acids (EFA) normally
found in the Western diet, the cartilage
cells produced less matrix and generated
a phenotype similar to tissue typical of
osteoarthritis. Once Adkisson placed the
cells into the EFA-free environment, they
produced a 3D cartilage matrix in the
absence of a scaffold.
This observation led Adkisson to formu-
late a special growth medium that
remains a trade secret and involves path-
ways other than fatty acidmetabolism. He
also showed that with aging there is a flip
of the fatty acid profile and proposed that
this change (the oxidation of polyunsatu-
rated fatty acids not normally present in
young growing cartilage) might be as-
sociated with cellular senescence and
dysfunction.
In 2000, Adkisson left academia to see
whether he could use these observations
to produce laboratory-grown cartilage
with harvested juvenile chondrocytes,
which produce cartilage much better
than adult cells. He and colleagues also
needed to expand chondrocytes from276 Chemistry & Biology 18, March 25, 2011juvenile donors for this technique to be
scaled commercially.
The team needed to trick chondrocytes
into thinking they were in the microenvi-
ronment of articular tissue so they would
retain their phenotype in laboratory cul-
tures. Otherwise, chondrocytes stretch
and flatten, producing type I collagen
rather than type II needed for hyaline
cartilage.
By 2007, Adkisson and colleagues
developed a now-patented way to ex-
pand chondrocytes through ten popula-
tion doublings and still retain ability to
produce cartilage matrix. ‘‘We went from
one donor being able to treat 25 recipients
to thousands of recipients. That’s what
really got this company going; the ability
to expand the cells and retain the pheno-
type and find multiple applications,’’ says
Seyedin.
Cartilage has another feature that
makes transplanted tissue less compli-
cated. Adkisson and colleagues proved
that chondrocytes truly are immune privi-
leged and identified the mechanism
(Adkisson et al., 2010). ‘‘This was purely
speculation or anecdotal before our publi-
cation,’’ says Adkisson. So patients who
receive donor cartilage do not need
immunosuppressants.
Today, a Broad Focus
With billions of human chondrocytes at
their disposal, ISTO broadened into the
spine market with NuQu, an injectible
percutaneous delivery of juvenile chon-
drocytes intended for patients with back
pain who do not respond to conservative
therapy after three months. The cells are
isolated, expanded, and put in a syringe
with fibrin and injected into spinal discs
in a minimally invasive procedure. This
cell-based therapy is intended to become
an improved therapeutic option for
resolving back pain associated with
degeneration of the intervertebral disc
nucleus, which is filled with hyaline carti-
lage. The intervertebral disc is a largeª2011 Elsevier Ltd All rights reservedcartilaginous structure that lies between
the vertebral bodies of the spine, cush-
ioning and anchoring them together.
Thus far, fifteen patients have been
treatedwith NuQu in a phase I clinical trial.
‘‘There is almost no rehabilitation. Three
hours after injection, patients can get up
and walk,’’ comments Seyedin. By April
2011, ISTO will complete analysis of the
6 month follow up and then submit safety
data to FDA.
In 2008, ISTO began generating rev-
enue through FDA 510 (k) approval with
InQu, the company’s bone graft extender
and substitute and their first product to
market. InQu combines PLGA, a biode-
gradable polymer, with hyaluronic acid,
a molecule critical for tissue repair and
regeneration. In procedures where a
bone graft is needed, as for vertebral
damage or as a bone extender for scoli-
osis deformities, the surgeon takes
a chip of bone from the pelvic bone, mixes
it with ceramics to induce bone growth,
and transfers the slurry to the injured area.
InQu eliminates the need for iliac crest
transfer and for ceramics. This platform
technology comes in strips, granules,
and paste that can be mixed with blood,
bone marrow, or morcelized with bone.
Company scientists are testing whether
InQu can be used to regenerate other
soft tissues that may be lost to injury or
disease, says Seyedin.
According to Seyedin, 2010 closed with
$10 million in revenue for ISTO. ‘‘We are
excited,’’ he says. ‘‘We are very excited.’’REFERENCES
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